<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>VERVE-101/102 - In Vivo Base Editing for PCSK9 | Comprehensive Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #8e44ad 0%, #3498db 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1600px;
            margin: 0 auto;
            background: rgba(255, 255, 255, 0.98);
            border-radius: 20px;
            overflow: hidden;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
        }
        
        .header {
            background: linear-gradient(135deg, #8e44ad 0%, #3498db 100%);
            color: white;
            padding: 50px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 50%;
            height: 200%;
            background: rgba(255,255,255,0.05);
            transform: rotate(45deg);
        }
        
        .dna-helix {
            position: absolute;
            top: 20px;
            right: 50px;
            width: 100px;
            height: 100px;
            opacity: 0.2;
            animation: rotate 20s linear infinite;
        }
        
        @keyframes rotate {
            from { transform: rotate(0deg); }
            to { transform: rotate(360deg); }
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 3.5em;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-subtitle {
            font-size: 1.3em;
            opacity: 0.95;
            margin-bottom: 5px;
        }
        
        .drug-mechanism {
            font-size: 1.6em;
            margin-top: 10px;
            padding: 12px 25px;
            background: rgba(255,255,255,0.2);
            border-radius: 30px;
            display: inline-block;
        }
        
        .status-badge {
            position: absolute;
            top: 50px;
            right: 50px;
            background: #ff5722;
            padding: 15px 30px;
            border-radius: 30px;
            font-weight: bold;
            box-shadow: 0 4px 10px rgba(0,0,0,0.2);
            animation: pulse 2s infinite;
        }
        
        .acquisition-badge {
            position: absolute;
            top: 100px;
            right: 50px;
            background: #4caf50;
            padding: 10px 20px;
            border-radius: 20px;
            font-size: 0.9em;
        }
        
        @keyframes pulse {
            0% { transform: scale(1); }
            50% { transform: scale(1.05); }
            100% { transform: scale(1); }
        }
        
        .content {
            padding: 40px;
        }
        
        .section {
            margin-bottom: 40px;
            background: #f8f9fa;
            padding: 35px;
            border-radius: 15px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.05);
            animation: fadeIn 0.6s ease-out;
        }
        
        .section-title {
            font-size: 2em;
            color: #333;
            margin-bottom: 25px;
            padding-bottom: 15px;
            border-bottom: 3px solid #8e44ad;
        }
        
        .mechanism-detail {
            background: white;
            padding: 25px;
            border-radius: 10px;
            margin-bottom: 20px;
            border-left: 4px solid #8e44ad;
        }
        
        .revolutionary-highlight {
            background: linear-gradient(135deg, #e74c3c 0%, #c0392b 100%);
            color: white;
            padding: 25px;
            border-radius: 10px;
            margin: 20px 0;
            font-size: 1.1em;
            box-shadow: 0 4px 10px rgba(231, 76, 60, 0.3);
        }
        
        .base-editing-visual {
            background: white;
            padding: 30px;
            border-radius: 10px;
            margin: 20px 0;
            border: 2px solid #8e44ad;
        }
        
        .editing-steps {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        
        .step-card {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            padding: 20px;
            border-radius: 10px;
            text-align: center;
            position: relative;
            transition: transform 0.3s;
        }
        
        .step-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 5px 20px rgba(142, 68, 173, 0.3);
        }
        
        .step-number {
            position: absolute;
            top: -15px;
            left: 50%;
            transform: translateX(-50%);
            background: #8e44ad;
            color: white;
            width: 30px;
            height: 30px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-weight: bold;
        }
        
        .timeline-container {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .timeline {
            position: relative;
            background: white;
            border-radius: 10px;
            padding: 30px;
        }
        
        .timeline-line {
            position: absolute;
            left: 60px;
            top: 0;
            bottom: 0;
            width: 4px;
            background: linear-gradient(180deg, #8e44ad 0%, #3498db 100%);
        }
        
        .timeline-item {
            position: relative;
            padding-left: 100px;
            margin-bottom: 35px;
            cursor: pointer;
            transition: transform 0.3s;
        }
        
        .timeline-item:hover {
            transform: translateX(10px);
        }
        
        .timeline-item.paused {
            opacity: 0.8;
        }
        
        .timeline-item.paused .timeline-dot {
            background: #ff5722;
            border-color: #ff5722;
        }
        
        .timeline-dot {
            position: absolute;
            left: 48px;
            top: 5px;
            width: 24px;
            height: 24px;
            background: white;
            border: 5px solid #8e44ad;
            border-radius: 50%;
            z-index: 1;
        }
        
        .timeline-dot.future {
            border-style: dashed;
            background: #f0f0f0;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #8e44ad;
            margin-bottom: 5px;
            font-size: 1.1em;
        }
        
        .timeline-content {
            background: #f8f9fa;
            padding: 20px;
            border-radius: 8px;
            transition: box-shadow 0.3s;
        }
        
        .timeline-tooltip {
            display: none;
            position: absolute;
            background: #333;
            color: white;
            padding: 15px;
            border-radius: 5px;
            font-size: 0.9em;
            z-index: 1000;
            max-width: 350px;
            box-shadow: 0 4px 10px rgba(0,0,0,0.3);
        }
        
        .timeline-item:hover .timeline-tooltip {
            display: block;
            left: 105%;
            top: 0;
            margin-left: 10px;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin-top: 20px;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 2px 10px rgba(0,0,0,0.05);
        }
        
        .trials-table th {
            background: linear-gradient(135deg, #8e44ad 0%, #3498db 100%);
            color: white;
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tr:hover {
            background: #f5f5f5;
        }
        
        .trial-paused {
            background: #fff3cd;
            color: #856404;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 0.9em;
        }
        
        .trial-ongoing {
            background: #cce5ff;
            color: #004085;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 0.9em;
        }
        
        .safety-concerns {
            background: #fff5f5;
            border: 2px solid #ff5722;
            border-radius: 10px;
            padding: 25px;
            margin: 20px 0;
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        
        .safety-item {
            background: white;
            padding: 20px;
            border-radius: 8px;
            border-left: 4px solid #ff5722;
        }
        
        .safety-item.resolved {
            border-left-color: #4caf50;
        }
        
        .safety-item.monitoring {
            border-left-color: #ff9800;
        }
        
        .safety-percentage {
            font-size: 1.5em;
            font-weight: bold;
            color: #333;
        }
        
        .efficacy-chart {
            background: white;
            padding: 30px;
            border-radius: 10px;
            margin-top: 20px;
        }
        
        .chart-container {
            position: relative;
            height: 400px;
            margin-top: 20px;
        }
        
        .chart-bar {
            position: absolute;
            bottom: 0;
            width: 100px;
            background: linear-gradient(180deg, #8e44ad 0%, #3498db 100%);
            border-radius: 5px 5px 0 0;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .chart-bar:hover {
            opacity: 0.8;
            transform: translateY(-5px);
        }
        
        .chart-label {
            position: absolute;
            bottom: -50px;
            width: 100px;
            text-align: center;
            font-size: 0.85em;
            color: #666;
        }
        
        .chart-value {
            position: absolute;
            top: -30px;
            width: 100px;
            text-align: center;
            font-weight: bold;
            color: #333;
            font-size: 1.1em;
        }
        
        .comparison-table {
            width: 100%;
            margin-top: 20px;
            background: white;
            border-radius: 10px;
            overflow: hidden;
        }
        
        .comparison-table th {
            background: #8e44ad;
            color: white;
            padding: 15px;
            text-align: left;
        }
        
        .comparison-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .commercial-factors {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin-top: 20px;
        }
        
        .factor-card {
            background: white;
            padding: 25px;
            border-radius: 10px;
            border-top: 4px solid #8e44ad;
        }
        
        .factor-title {
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            font-size: 1.2em;
        }
        
        .pricing-model {
            background: linear-gradient(135deg, #f39c12 0%, #e67e22 100%);
            color: white;
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
        }
        
        .progress-bar {
            background: #e0e0e0;
            border-radius: 10px;
            height: 12px;
            overflow: hidden;
            margin-top: 10px;
        }
        
        .progress-fill {
            height: 100%;
            background: linear-gradient(90deg, #8e44ad 0%, #3498db 100%);
            border-radius: 10px;
            transition: width 1s ease-in-out;
        }
        
        .precedent-card {
            background: #f0f4ff;
            border: 1px solid #3498db;
            border-radius: 10px;
            padding: 20px;
            margin: 15px 0;
        }
        
        .warning-box {
            background: #fff3cd;
            border-left: 5px solid #ffc107;
            padding: 20px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        .success-box {
            background: #d4edda;
            border-left: 5px solid #28a745;
            padding: 20px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .no-data-badge {
            background: #f8d7da;
            color: #721c24;
            padding: 5px 10px;
            border-radius: 5px;
            font-size: 0.9em;
            display: inline-block;
        }
        
        .projection-badge {
            background: #cce5ff;
            color: #004085;
            padding: 5px 10px;
            border-radius: 5px;
            font-size: 0.9em;
            display: inline-block;
        }
        
        .critical-info {
            background: #ffe5e5;
            border: 2px solid #ff0000;
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
        }
        
        .pipeline-visual {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 10px;
        }
        
        .pipeline-item {
            flex: 1;
            text-align: center;
            padding: 15px;
            margin: 0 10px;
            border-radius: 8px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            transition: transform 0.3s;
        }
        
        .pipeline-item:hover {
            transform: translateY(-5px);
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }
        
        .pipeline-item.active {
            background: linear-gradient(135deg, #8e44ad 0%, #3498db 100%);
            color: white;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <svg class="dna-helix" viewBox="0 0 100 100">
                <path d="M30,10 Q50,30 70,10 T70,50 Q50,70 30,50 T30,90" stroke="white" stroke-width="2" fill="none"/>
                <path d="M70,10 Q50,30 30,10 T30,50 Q50,70 70,50 T70,90" stroke="white" stroke-width="2" fill="none"/>
            </svg>
            <div class="drug-title">
                <div class="drug-name">VERVE-101 / VERVE-102</div>
                <div class="drug-subtitle">Verve Therapeutics → Eli Lilly (Acquired July 2025)</div>
                <div class="drug-mechanism">First-in-Class In Vivo Base Editing Therapy</div>
            </div>
            <div class="status-badge">PHASE 1 - PAUSED/PIVOTED</div>
            <div class="acquisition-badge">$1B Acquisition Complete</div>
        </div>
        
        <div class="content">
            <!-- Revolutionary Technology Overview -->
            <div class="section">
                <h2 class="section-title">🧬 Revolutionary Gene Editing Technology</h2>
                
                <div class="revolutionary-highlight">
                    <strong>🎯 Paradigm Shift:</strong> One-time intravenous infusion permanently inactivates PCSK9 gene in liver cells, potentially providing lifelong LDL-C reduction. This is not a drug - it's a functional cure for high cholesterol through precise DNA editing.
                </div>
                
                <div class="base-editing-visual">
                    <h3>How Base Editing Works - The VERVE Approach</h3>
                    <div class="editing-steps">
                        <div class="step-card">
                            <div class="step-number">1</div>
                            <h4>Delivery</h4>
                            <p>Lipid nanoparticle (LNP) carries mRNA for base editor + guide RNA to liver via IV infusion</p>
                        </div>
                        <div class="step-card">
                            <div class="step-number">2</div>
                            <h4>Targeting</h4>
                            <p>Guide RNA directs base editor to specific PCSK9 gene location in hepatocytes</p>
                        </div>
                        <div class="step-card">
                            <div class="step-number">3</div>
                            <h4>Editing</h4>
                            <p>Adenine base editor (ABE) makes precise A→G change without cutting DNA</p>
                        </div>
                        <div class="step-card">
                            <div class="step-number">4</div>
                            <h4>Result</h4>
                            <p>Introduces stop codon in PCSK9, permanently halting protein production</p>
                        </div>
                        <div class="step-card">
                            <div class="step-number">5</div>
                            <h4>Effect</h4>
                            <p>50-70% of hepatocytes edited, 80-90% PCSK9 knockdown achieved</p>
                        </div>
                        <div class="step-card">
                            <div class="step-number">6</div>
                            <h4>Outcome</h4>
                            <p>50-70% LDL-C reduction sustained indefinitely (>2.5 years in primates)</p>
                        </div>
                    </div>
                </div>
                
                <div class="mechanism-detail">
                    <h3>Technical Specifications</h3>
                    <ul style="margin-left: 20px; line-height: 1.8;">
                        <li><strong>Editor Type:</strong> Adenine Base Editor (ABE) - Cas9 nickase fused to TadA adenine deaminase</li>
                        <li><strong>Target:</strong> PCSK9 gene exon 1 - introduces premature stop codon</li>
                        <li><strong>Delivery:</strong> Liver-targeted LNP (similar to COVID mRNA vaccines but optimized for hepatocytes)</li>
                        <li><strong>Editing Efficiency:</strong> 50-70% of hepatocytes in therapeutic dose range</li>
                        <li><strong>Off-target Rate:</strong> <0.1% genome-wide (extensive WGS validation)</li>
                        <li><strong>Germline Risk:</strong> Minimal - no significant gonadal LNP distribution</li>
                    </ul>
                </div>
                
                <div class="mechanism-detail">
                    <h3>VERVE-101 vs VERVE-102 - Key Differences</h3>
                    <table class="comparison-table">
                        <thead>
                            <tr>
                                <th>Feature</th>
                                <th>VERVE-101</th>
                                <th>VERVE-102 (Improved)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>LNP Formulation</td>
                                <td>First-generation LNP</td>
                                <td>GalNAc-conjugated LNP (enhanced liver targeting)</td>
                            </tr>
                            <tr>
                                <td>Status</td>
                                <td>Paused April 2024 (safety concerns)</td>
                                <td>Active development - IND cleared March 2025</td>
                            </tr>
                            <tr>
                                <td>Tolerability</td>
                                <td>Grade 3 ALT elevations, thrombocytopenia</td>
                                <td>Expected improved safety profile</td>
                            </tr>
                            <tr>
                                <td>Potency</td>
                                <td>0.1-0.6 mg/kg doses tested</td>
                                <td>Potentially lower doses needed</td>
                            </tr>
                            <tr>
                                <td>Trial</td>
                                <td>Heart-1 (paused)</td>
                                <td>Heart-2 (starting H2 2025)</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
                
                <div class="pipeline-visual">
                    <div class="pipeline-item active">
                        <h4>VERVE-102</h4>
                        <p>PCSK9 (HeFH/ASCVD)</p>
                        <small>Phase 1b/2 Starting</small>
                    </div>
                    <div class="pipeline-item">
                        <h4>VERVE-201</h4>
                        <p>ANGPTL3 (HoFH)</p>
                        <small>IND-Enabling</small>
                    </div>
                    <div class="pipeline-item">
                        <h4>VERVE-301</h4>
                        <p>Lp(a) Reduction</p>
                        <small>Research Stage</small>
                    </div>
                </div>
            </div>
            
            <!-- Comprehensive Regulatory Timeline -->
            <div class="section">
                <h2 class="section-title">🏛️ Regulatory Journey - First-in-Human Gene Editing</h2>
                
                <div class="warning-box">
                    <strong>⚠️ Regulatory Complexity:</strong> As the first in vivo base editing therapy, VERVE faces unprecedented regulatory scrutiny. Every step sets precedent for the entire field.
                </div>
                
                <h3>FDA Timeline - Detailed Progression</h3>
                <div class="timeline">
                    <div class="timeline-line"></div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2019-2022</div>
                        <div class="timeline-content">
                            <strong>Preclinical Development</strong>
                            <div class="timeline-tooltip">
                                Extensive non-human primate studies (n~50)<br>
                                • 89% PCSK9 reduction achieved<br>
                                • 69% LDL-C reduction sustained >2 years<br>
                                • No significant off-target edits detected<br>
                                • Established safety profile for IND submission
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">October 2022</div>
                        <div class="timeline-content">
                            <strong>IND Submission for VERVE-101</strong>
                            <div class="timeline-tooltip">
                                First IND for in vivo base editing submitted to FDA<br>
                                Comprehensive package including:<br>
                                • Primate durability data<br>
                                • Off-target analysis<br>
                                • Manufacturing specifications
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item paused">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">November 2022</div>
                        <div class="timeline-content">
                            <strong>⚠️ FDA CLINICAL HOLD</strong>
                            <div class="timeline-tooltip">
                                FDA placed hold citing critical concerns:<br>
                                • Germline editing risks (hereditary changes)<br>
                                • Need for more off-target data in human cells<br>
                                • Potency differences between species<br>
                                • LNP safety profile questions<br>
                                • Long-term monitoring requirements
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2022-2023</div>
                        <div class="timeline-content">
                            <strong>Ex-US Trial Initiation</strong>
                            <div class="timeline-tooltip">
                                While FDA hold active, trials began in:<br>
                                • New Zealand (Medsafe approval)<br>
                                • United Kingdom (MHRA approval)<br>
                                First patients dosed internationally<br>
                                Generated real-world human data
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">October 2023</div>
                        <div class="timeline-content">
                            <strong>✓ FDA Hold Lifted</strong>
                            <div class="timeline-tooltip">
                                Verve provided comprehensive response:<br>
                                • No gonadal LNP distribution in primates<br>
                                • Genome-wide off-target <0.1%<br>
                                • Early human data from ex-US trials<br>
                                • Enhanced safety monitoring protocols<br>
                                US enrollment in Heart-1 authorized
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item paused">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">April 2024</div>
                        <div class="timeline-content">
                            <strong>⚠️ Voluntary Pause - Safety Signal</strong>
                            <div class="timeline-tooltip">
                                Heart-1 trial paused due to:<br>
                                • Grade 3 ALT elevation in patient<br>
                                • Thrombocytopenia observed<br>
                                • Decision to pivot to VERVE-102<br>
                                • Enhanced LNP formulation needed
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">March 2025</div>
                        <div class="timeline-content">
                            <strong>VERVE-102 IND Cleared</strong>
                            <div class="timeline-tooltip">
                                FDA approves improved version:<br>
                                • GalNAc-conjugated LNP<br>
                                • Better liver targeting<br>
                                • Expected improved tolerability<br>
                                • Heart-2 trial authorized
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">July 25, 2025</div>
                        <div class="timeline-content">
                            <strong>🎯 Eli Lilly Acquisition Complete</strong>
                            <div class="timeline-tooltip">
                                $1 billion acquisition finalized<br>
                                • Enhanced resources for development<br>
                                • Regulatory expertise from big pharma<br>
                                • Accelerated timeline potential<br>
                                • Global infrastructure access
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot future"></div>
                        <div class="timeline-date">H2 2025 <span class="projection-badge">Expected</span></div>
                        <div class="timeline-content">
                            <strong>Heart-2 First Patient Dosed</strong>
                            <div class="timeline-tooltip">
                                Phase 1b/2 trial initiation<br>
                                • n=100 planned enrollment<br>
                                • Randomized, placebo-controlled<br>
                                • US/UK/NZ sites
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot future"></div>
                        <div class="timeline-date">2026 <span class="projection-badge">Projected</span></div>
                        <div class="timeline-content">
                            <strong>Heart-2 Initial Data</strong>
                            <div class="timeline-tooltip">
                                12-week primary endpoint data<br>
                                52-week durability assessment<br>
                                Safety profile establishment
                            </div>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-dot future"></div>
                        <div class="timeline-date">2028-2030 <span class="projection-badge">Potential</span></div>
                        <div class="timeline-content">
                            <strong>BLA Submission</strong>
                            <div class="timeline-tooltip">
                                If Phase 3 successful:<br>
                                • Multi-year follow-up required<br>
                                • Post-marketing registry mandated<br>
                                • Orphan Drug Designation possible
                            </div>
                        </div>
                    </div>
                </div>
                
                <h3 style="margin-top: 30px;">EMA & Global Regulatory Status</h3>
                <div class="mechanism-detail">
                    <ul style="margin-left: 20px; line-height: 1.8;">
                        <li><strong>EMA:</strong> More permissive initially - no hold while FDA paused. No PRIME designation yet</li>
                        <li><strong>MHRA (UK):</strong> First to approve human trials - enabled critical early data</li>
                        <li><strong>Medsafe (NZ):</strong> Similarly progressive - allowed first-in-human dosing</li>
                        <li><strong>Future:</strong> MAA expected post-Phase 3 (~2030), centralized EU procedure likely</li>
                        <li><strong>Global Harmonization:</strong> FDA/EMA likely to align via Parallel Scientific Advice</li>
                    </ul>
                </div>
            </div>
            
            <!-- Comprehensive Clinical Trials -->
            <div class="section">
                <h2 class="section-title">🔬 Clinical Development Program - Detailed Analysis</h2>
                
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial/Program</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Design</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results/Status</th>
                            <th>Timeline</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Preclinical NHP</strong></td>
                            <td>Pre</td>
                            <td>~50</td>
                            <td>Non-human primates</td>
                            <td>Single dose escalation</td>
                            <td>Safety, efficacy, durability</td>
                            <td>89% PCSK9↓, 69% LDL↓ >2yr</td>
                            <td>2019-2022</td>
                        </tr>
                        <tr>
                            <td><strong>Heart-1</strong><br>(NCT05398029)</td>
                            <td>1b</td>
                            <td>44 planned<br>~12 dosed</td>
                            <td>HeFH/ASCVD</td>
                            <td>Open-label, dose-escalation<br>0.1-0.6 mg/kg IV</td>
                            <td>Safety/AEs to 5 years</td>
                            <td><span class="trial-paused">PAUSED</span><br>83% PCSK9↓, 55% LDL↓<br>Grade 3 ALT/thrombocytopenia</td>
                            <td>2022-2024</td>
                        </tr>
                        <tr>
                            <td><strong>Heart-2</strong><br>(VERVE-102)</td>
                            <td>1b/2</td>
                            <td>~100</td>
                            <td>HeFH/premature CAD</td>
                            <td>Randomized, placebo-controlled</td>
                            <td>Safety, % LDL-C at 12 wk</td>
                            <td><span class="trial-ongoing">Starting H2 2025</span></td>
                            <td>2025-2027</td>
                        </tr>
                        <tr>
                            <td><strong>VERVE-201</strong><br>(ANGPTL3)</td>
                            <td>IND</td>
                            <td>-</td>
                            <td>HoFH/HTG</td>
                            <td>Preclinical development</td>
                            <td>-</td>
                            <td>IND filing expected 2026</td>
                            <td>2026+</td>
                        </tr>
                        <tr>
                            <td><strong>Long-term Registry</strong></td>
                            <td>4</td>
                            <td>All pts</td>
                            <td>All treated patients</td>
                            <td>Observational registry</td>
                            <td>Long-term safety/efficacy</td>
                            <td>5-15 year follow-up planned</td>
                            <td>Ongoing</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="critical-info">
                    <h3>⚠️ Critical Trial Insights</h3>
                    <ul style="margin-left: 20px; line-height: 1.8;">
                        <li><strong>Heart-1 Pause:</strong> Single patient with Grade 3 ALT elevation and thrombocytopenia at 0.6 mg/kg led to complete program re-evaluation</li>
                        <li><strong>Dose-Escalation Protocol:</strong> Extremely cautious - single patient dosing with extended observation periods</li>
                        <li><strong>Steroid Premedication:</strong> Required to mitigate potential immune responses to Cas9 (70% humans have pre-existing antibodies)</li>
                        <li><strong>Biopsy Requirements:</strong> Some protocols include liver biopsies for off-target assessment</li>
                        <li><strong>No CVOT Yet:</strong> Approval will rely on LDL-C surrogate with post-marketing outcomes commitment</li>
                    </ul>
                </div>
            </div>
            
            <!-- Efficacy Data Visualization -->
            <div class="section">
                <h2 class="section-title">📈 Efficacy Profile - Current & Projected</h2>
                
                <div class="efficacy-chart">
                    <h3>Biomarker Changes - Heart-1 Interim Data</h3>
                    <div class="chart-container">
                        <div class="chart-bar" style="height: 83%; left: 50px;">
                            <div class="chart-value">83%</div>
                            <div class="chart-label">PCSK9<br>Reduction<br>(High dose)</div>
                        </div>
                        <div class="chart-bar" style="height: 55%; left: 200px;">
                            <div class="chart-value">55%</div>
                            <div class="chart-label">LDL-C<br>Reduction<br>(Day 180)</div>
                        </div>
                        <div class="chart-bar" style="height: 46%; left: 350px;">
                            <div class="chart-value">46%</div>
                            <div class="chart-label">LDL-C<br>Reduction<br>(Low dose)</div>
                        </div>
                        <div class="chart-bar" style="height: 45%; left: 500px; background: linear-gradient(180deg, #9e9e9e 0%, #616161 100%);">
                            <div class="chart-value">~45%</div>
                            <div class="chart-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="chart-bar" style="height: 30%; left: 650px; background: linear-gradient(180deg, #ff9800 0%, #f57c00 100%);">
                            <div class="chart-value">~30%</div>
                            <div class="chart-label">Lp(a)<br>Reduction</div>
                        </div>
                        <div class="chart-bar" style="height: 88%; left: 800px; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                            <div class="chart-value">88%</div>
                            <div class="chart-label">Genetic<br>CAD Risk↓<br>(Projection)</div>
                        </div>
                    </div>
                </div>
                
                <div class="mechanism-detail" style="margin-top: 30px;">
                    <h3>Durability Profile - The "One-and-Done" Promise</h3>
                    <ul style="margin-left: 20px; line-height: 1.8;">
                        <li><strong>Primate Data:</strong> >2.5 years sustained effect with no rebound</li>
                        <li><strong>Human Projection:</strong> Expected lifelong effect from single infusion</li>
                        <li><strong>Editing Coverage:</strong> 50-70% hepatocytes edited at therapeutic doses</li>
                        <li><strong>Comparison to Genetics:</strong> Mimics PCSK9 R46L carriers (88% lower CAD risk)</li>
                        <li><strong>Theoretical MACE Reduction:</strong> 50-80% lifetime risk reduction if given early</li>
                    </ul>
                </div>
            </div>
            
            <!-- Comprehensive Safety Analysis -->
            <div class="section">
                <h2 class="section-title">🛡️ Safety Profile - Critical Considerations</h2>
                
                <div class="safety-concerns">
                    <h3>⚠️ Key Safety Concerns & Mitigation Strategies</h3>
                    <div class="safety-grid">
                        <div class="safety-item">
                            <div class="safety-percentage">Grade 3 ALT</div>
                            <div>Hepatotoxicity Signal</div>
                            <small>Led to VERVE-101 pause, addressed in -102</small>
                        </div>
                        <div class="safety-item">
                            <div class="safety-percentage">Thrombocytopenia</div>
                            <div>Platelet Drop</div>
                            <small>Observed at 0.6 mg/kg dose</small>
                        </div>
                        <div class="safety-item resolved">
                            <div class="safety-percentage"><0.1%</div>
                            <div>Off-Target Edits</div>
                            <small>Extensive WGS validation completed</small>
                        </div>
                        <div class="safety-item resolved">
                            <div class="safety-percentage">Minimal</div>
                            <div>Germline Risk</div>
                            <small>No gonadal LNP distribution shown</small>
                        </div>
                        <div class="safety-item monitoring">
                            <div class="safety-percentage">70%</div>
                            <div>Pre-existing Anti-Cas9</div>
                            <small>Managed with steroid premedication</small>
                        </div>
                        <div class="safety-item monitoring">
                            <div class="safety-percentage">20-30%</div>
                            <div>Infusion Reactions</div>
                            <small>Mild fever, headache - transient</small>
                        </div>
                    </div>
                </div>
                
                <div class="mechanism-detail">
                    <h3>Long-term Safety Monitoring Requirements</h3>
                    <ul style="margin-left: 20px; line-height: 1.8;">
                        <li><strong>5-15 Year Follow-up:</strong> All patients in mandatory registry</li>
                        <li><strong>Cancer Surveillance:</strong> Annual screening for hepatocellular carcinoma</li>
                        <li><strong>Genomic Monitoring:</strong> Periodic WGS of blood cells for emergent off-targets</li>
                        <li><strong>Liver Function:</strong> Quarterly LFTs for first year, then biannual</li>
                        <li><strong>Reproductive Health:</strong> Counseling on theoretical germline risks</li>
                        <li><strong>Neurocognitive:</strong> Annual assessments (though no signals expected)</li>
                    </ul>
                </div>
                
                <div class="success-box">
                    <h3>✓ Safety Advantages vs Other Gene Therapies</h3>
                    <ul style="margin-left: 20px;">
                        <li>No double-strand DNA breaks (unlike CRISPR-Cas9)</li>
                        <li>No viral vectors (avoiding insertional mutagenesis)</li>
                        <li>Liver-specific targeting (limited systemic exposure)</li>
                        <li>Single nucleotide change (minimal genomic disruption)</li>
                        <li>Precedent from natural PCSK9 LOF humans (healthy phenotype)</li>
                    </ul>
                </div>
            </div>
            
            <!-- Commercial & Market Analysis -->
            <div class="section">
                <h2 class="section-title">💰 Commercial Strategy & Market Disruption</h2>
                
                <div class="pricing-model">
                    <h3>💵 Pricing Models Under Consideration</h3>
                    <p><strong>Expected Range: $1-2 Million</strong> - Justified by lifetime benefit vs chronic therapy costs</p>
                    <ul style="margin-top: 15px; margin-left: 20px;">
                        <li>Annuity payments over 5-10 years</li>
                        <li>Outcomes-based rebates (refund if LDL rebounds)</li>
                        <li>Risk-sharing with payers</li>
                        <li>Government negotiation under IRA likely</li>
                    </ul>
                </div>
                
                <div class="commercial-factors">
                    <div class="factor-card">
                        <div class="factor-title">Target Population</div>
                        <p><strong>Initial:</strong> HeFH (~1 in 250 people)</p>
                        <p><strong>Expansion:</strong> High-risk ASCVD</p>
                        <p><strong>Ultimate:</strong> Primary prevention?</p>
                        <div class="progress-bar">
                            <div class="progress-fill" style="width: 20%;"></div>
                        </div>
                        <small>Market penetration potential</small>
                    </div>
                    
                    <div class="factor-card">
                        <div class="factor-title">Payer Friction Points</div>
                        <ul style="margin-left: 20px;">
                            <li>High upfront cost</li>
                            <li>Budget impact concerns</li>
                            <li>Patient insurance churn</li>
                            <li>Irreversibility concerns</li>
                        </ul>
                        <div class="progress-bar">
                            <div class="progress-fill" style="width: 70%;"></div>
                        </div>
                        <small>Reimbursement challenge level</small>
                    </div>
                    
                    <div class="factor-card">
                        <div class="factor-title">Delivery Infrastructure</div>
                        <p>Specialized centers required initially</p>
                        <p>Similar to CAR-T therapy model</p>
                        <p>Eventually may expand to infusion centers</p>
                        <div class="progress-bar">
                            <div class="progress-fill" style="width: 30%;"></div>
                        </div>
                        <small>Current infrastructure readiness</small>
                    </div>
                    
                    <div class="factor-card">
                        <div class="factor-title">Competitive Advantage</div>
                        <p><strong>vs Chronic Rx:</strong> No adherence issues</p>
                        <p><strong>vs Inclisiran:</strong> True one-time treatment</p>
                        <p><strong>Economic:</strong> Break-even ~15-20 years</p>
                        <div class="progress-bar">
                            <div class="progress-fill" style="width: 90%;"></div>
                        </div>
                        <small>Theoretical advantage if safe</small>
                    </div>
                </div>
                
                <div class="mechanism-detail" style="margin-top: 30px;">
                    <h3>Market Disruption Scenarios</h3>
                    <table class="comparison-table">
                        <thead>
                            <tr>
                                <th>Timeframe</th>
                                <th>Conservative Scenario</th>
                                <th>Base Case</th>
                                <th>Optimistic Scenario</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>2025-2027</td>
                                <td>Clinical trials only</td>
                                <td>Phase 2/3 progression</td>
                                <td>Accelerated approval pathway</td>
                            </tr>
                            <tr>
                                <td>2028-2030</td>
                                <td>Limited approval for HoFH</td>
                                <td>HeFH approval, slow uptake</td>
                                <td>Broad HeFH use, ASCVD trials</td>
                            </tr>
                            <tr>
                                <td>2030-2035</td>
                                <td>Niche therapy for severe cases</td>
                                <td>Standard for genetic dyslipidemias</td>
                                <td>Primary prevention consideration</td>
                            </tr>
                            <tr>
                                <td>Market Impact</td>
                                <td>$500M peak sales</td>
                                <td>$2-3B peak sales</td>
                                <td>$5B+ transformative impact</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            
            <!-- Precedents and Comparisons -->
            <div class="section">
                <h2 class="section-title">📚 Historical Precedents & Competitive Landscape</h2>
                
                <h3>Gene Therapy Precedents</h3>
                <div class="precedent-card">
                    <h4>Casgevy (Vertex/CRISPR Therapeutics)</h4>
                    <p><strong>Approval:</strong> FDA/EMA 2023 for sickle cell disease</p>
                    <p><strong>Price:</strong> $2.2 million</p>
                    <p><strong>Relevance:</strong> First CRISPR therapy approved, but ex vivo editing (not in vivo like VERVE)</p>
                    <p><strong>Lessons:</strong> Regulatory pathway possible, high price accepted for genetic diseases</p>
                </div>
                
                <div class="precedent-card">
                    <h4>NTLA-2001 (Intellia/Regeneron)</h4>
                    <p><strong>Status:</strong> Phase 3 for ATTR amyloidosis</p>
                    <p><strong>Similarity:</strong> In vivo CRISPR via LNP delivery to liver</p>
                    <p><strong>Results:</strong> 87% TTR reduction, no major safety issues</p>
                    <p><strong>Relevance:</strong> Most similar precedent - shows in vivo editing feasible</p>
                </div>
                
                <div class="precedent-card">
                    <h4>Zolgensma (Novartis)</h4>
                    <p><strong>Approval:</strong> FDA/EMA 2019 for SMA</p>
                    <p><strong>Price:</strong> $2.1 million</p>
                    <p><strong>Model:</strong> One-time AAV gene therapy</p>
                    <p><strong>Lessons:</strong> Payer acceptance of high-cost cures, but 20-30% abandonment rate</p>
                </div>
                
                <div class="mechanism-detail" style="margin-top: 30px;">
                    <h3>Competitive Positioning vs Other PCSK9 Approaches</h3>
                    <table class="comparison-table">
                        <thead>
                            <tr>
                                <th>Approach</th>
                                <th>Frequency</th>
                                <th>Efficacy</th>
                                <th>Convenience</th>
                                <th>Reversibility</th>
                                <th>Timeline to Market</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>VERVE Gene Editing</strong></td>
                                <td>Once lifetime</td>
                                <td>50-70% LDL↓</td>
                                <td>Ultimate (one-time)</td>
                                <td>Irreversible</td>
                                <td>2028-2030</td>
                            </tr>
                            <tr>
                                <td>Inclisiran (siRNA)</td>
                                <td>2x/year</td>
                                <td>50% LDL↓</td>
                                <td>High</td>
                                <td>Reversible</td>
                                <td>Approved</td>
                            </tr>
                            <tr>
                                <td>PCSK9 mAbs</td>
                                <td>Monthly</td>
                                <td>60% LDL↓</td>
                                <td>Moderate</td>
                                <td>Reversible</td>
                                <td>Approved</td>
                            </tr>
                            <tr>
                                <td>Oral PCSK9i (MK-0616)</td>
                                <td>Daily</td>
                                <td>60% LDL↓</td>
                                <td>High (oral)</td>
                                <td>Reversible</td>
                                <td>2026-2027</td>
                            </tr>
                            <tr>
                                <td>Lerodalcibep</td>
                                <td>Monthly</td>
                                <td>60% LDL↓</td>
                                <td>Moderate</td>
                                <td>Reversible</td>
                                <td>2024</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            
            <!-- Future Outlook -->
            <div class="section">
                <h2 class="section-title">🔮 Future Outlook & Strategic Implications</h2>
                
                <div class="revolutionary-highlight">
                    <h3>🚀 Paradigm Shift Potential</h3>
                    <p>If successful, VERVE represents the holy grail of cardiovascular medicine - a one-time cure for high cholesterol. This could fundamentally transform how we approach cardiovascular disease prevention, shifting from lifelong medication to one-time genetic correction.</p>
                </div>
                
                <div class="mechanism-detail">
                    <h3>Critical Success Factors</h3>
                    <ul style="margin-left: 20px; line-height: 1.8;">
                        <li><strong>Safety Validation:</strong> Must prove no long-term adverse effects over 5+ years</li>
                        <li><strong>Efficacy Durability:</strong> Must demonstrate truly permanent LDL reduction</li>
                        <li><strong>Manufacturing Scale:</strong> Must achieve consistent, scalable production</li>
                        <li><strong>Regulatory Alignment:</strong> Must satisfy FDA/EMA's unprecedented scrutiny</li>
                        <li><strong>Payer Acceptance:</strong> Must develop sustainable reimbursement models</li>
                        <li><strong>Public Trust:</strong> Must overcome "gene editing" fears through transparency</li>
                    </ul>
                </div>
                
                <div class="warning-box">
                    <h3>⚠️ Key Risks & Uncertainties</h3>
                    <ul style="margin-left: 20px;">
                        <li>Unknown long-term effects of permanent PCSK9 knockout</li>
                        <li>Potential for delayed adverse events (cancer, immune issues)</li>
                        <li>Regulatory requirements may extend timeline significantly</li>
                        <li>Public/physician acceptance of irreversible therapy uncertain</li>
                        <li>Competition from safer/simpler approaches may limit uptake</li>
                    </ul>
                </div>
                
                <div class="success-box">
                    <h3>✓ Why Lilly's Acquisition Makes Sense</h3>
                    <ul style="margin-left: 20px;">
                        <li>Hedging across entire PCSK9 landscape (pills, injections, gene editing)</li>
                        <li>Access to potentially transformative technology</li>
                        <li>Leverage existing cardiovascular infrastructure</li>
                        <li>First-mover advantage in gene editing for common diseases</li>
                        <li>Platform potential beyond PCSK9 (ANGPTL3, Lp(a), etc.)</li>
                    </ul>
                </div>
                
                <div class="mechanism-detail" style="margin-top: 30px; background: linear-gradient(135deg, #e3f2fd 0%, #bbdefb 100%); border: 2px solid #2196f3;">
                    <h3>📊 Bottom Line Assessment</h3>
                    <p style="font-size: 1.1em; line-height: 1.8;">
                        <strong>Near-term (2025-2027):</strong> Minimal commercial impact - still in trials<br>
                        <strong>Medium-term (2028-2030):</strong> Potential approval for severe genetic dyslipidemia<br>
                        <strong>Long-term (2030+):</strong> Could revolutionize CV prevention if safety proven<br><br>
                        <strong>Probability of Success:</strong> ~40-50% for HeFH indication by 2030<br>
                        <strong>Market Disruption Potential:</strong> Extreme if successful, minimal if safety issues emerge<br>
                        <strong>Strategic Value:</strong> Critical optionality for future of lipid management
                    </p>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        // Animate progress bars on scroll
        const observerOptions = {
            threshold: 0.5
        };
        
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const fills = entry.target.querySelectorAll('.progress-fill');
                    fills.forEach(fill => {
                        const width = fill.style.width;
                        fill.style.width = '0';
                        setTimeout(() => {
                            fill.style.width = width;
                        }, 100);
                    });
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.commercial-factors, .factor-card').forEach(el => {
            observer.observe(el);
        });
        
        // Animate chart bars on scroll
        const chartObserver = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.chart-bar');
                    bars.forEach((bar, index) => {
                        const height = bar.style.height;
                        bar.style.height = '0';
                        setTimeout(() => {
                            bar.style.height = height;
                        }, index * 100);
                    });
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.chart-container').forEach(el => {
            chartObserver.observe(el);
        });
        
        // Add interactive hover effects to pipeline items
        document.querySelectorAll('.pipeline-item').forEach(item => {
            item.addEventListener('mouseenter', function() {
                this.style.transform = 'translateY(-5px) scale(1.05)';
            });
            item.addEventListener('mouseleave', function() {
                this.style.transform = 'translateY(0) scale(1)';
            });
        });
        
        // Animate timeline items sequentially
        const timelineObserver = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const items = entry.target.querySelectorAll('.timeline-item');
                    items.forEach((item, index) => {
                        setTimeout(() => {
                            item.style.opacity = '1';
                            item.style.transform = 'translateX(0)';
                        }, index * 150);
                    });
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.timeline').forEach(el => {
            const items = el.querySelectorAll('.timeline-item');
            items.forEach(item => {
                item.style.opacity = '0';
                item.style.transform = 'translateX(-20px)';
                item.style.transition = 'all 0.5s ease';
            });
            timelineObserver.observe(el);
        });
    </script>
</body>
</html>